Under the umbrella of the BEAT‐AML master trial the triplet combination was moved into first‐line treatment of elderly non‐fit NPM1‐mutated or KMT2A‐rearranged patients: In this ongoing phase I trial, Revumenib is assessed in combination with Azacitidine (AZA)/VEN in patients previously untreated NPM1‐mutated or KMT2A‐rearranged leukemias.126. This evidence concerns the gene NPM1 and acute myeloid leukemia.